Kanekwa Zyambo

Ms. Kanekwa Zyambo

TROPGAN
+1

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2017 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PKPatrick Kaonga
Patrick Kaonga
EKEvans Kaimoyo
Evans Kaimoyo
EBEllen Besa
Ellen Besa
KZKanekwa Zyambo
Kanekwa Zyambo
ESEdford Sinkala
Edford Sinkala
PKPaul Kelly
Paul Kelly
Microbial translocation is a poorly understood consequence of several disorders such as environmental enteropathy (EE) and hepatosplenic schistosomiasis (HSS). Herein, we compared biomarkers of microbial origin and immune activation in adults with these disorders and in healthy controls. A cross-sectional study was conducted in participants with EE recruited from Misisi compound, Lusaka, Zambia; HSS patients and healthy controls from the University Teaching Hospital, Lusaka. Plasma lipopolysaccharides (LPSs) was measured by limulus amoebocyte lysate assay, plasma 16S ribosomal RNA (16S rRNA) gene copy number was quantified by quantitative real-time polymerase chain reaction, Toll-like receptor ligand (TLRL) activity by QUANTI-Blue detection medium, and cytokines from cell culture supernatant by Cytometric Bead Array. In univariate analysis LPS, 16S rRNA gene copy number, and TLR activity were all high and correlated with each other and with cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-10, and IL-4 secreted by the RAW-Blue cells. After controlling for baseline characteristic, biomarkers of microbial translocation in blood were predictors of TNF-α, IL-6, and IL-10 activation in cell culture supernatant from EE participants and HSS patients but not in healthy controls. TLR activity showed the strongest correlation with TNF-α. These data provide correlative evidence that microbial translocation contributes to systemic cytokine activation in two disorders common in the tropics, with total TLR ligand estimation showing the strongest correlation with TNF-α (r = 0.66, P < 0.001).

1 April 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
ESEdford Sinkala
Edford Sinkala
MVMichael Vinikoor
Michael Vinikoor
KZKanekwa Zyambo
Kanekwa Zyambo
EBEllen Besa
Ellen Besa
BNBright Nsokolo
Bright Nsokolo
PKPaul Kelly
Paul Kelly
Hepatosplenic schistosomiasis (HSS) complicates portal hypertension, leading to life-threatening variceal bleeding. Variceal bleeding is associated with increased portal vein diameter (PVD). Beta-blockers prevent variceal bleeding. It is unclear whether beta-blockers such as propranolol can reduce PVD in HSS. We aimed to explore the effect of propranolol on PVD in HSS. A longitudinal study was conducted at the University Teaching Hospital, Zambia, as an extension of a clinical trial of rifaximin undertaken to test the hypothesis that rifaximin could reduce bacterial translocation in HSS. We randomized 85 adults to either rifaximin and standard care, or propranolol-based standard care only for 42 days. We then followed up all the patients on propranolol up to day 180. We used ultrasound to measure PVD at baseline and day 180. The primary outcome was reduction in PVD. Beta-blockade and splenic size reduction were secondary outcomes. Portal vein diameter reduced after 180 days of propranolol therapy from median 12 mm (interquartile range (IQR): 11–14) to median 10 mm (IQR: 9–13) (P < 0.001). The pulse rate reduced from baseline median 70 beats/minute (IQR: 66–80) to 65 beats/minute (IQR: 60–70) by day 180 (P = 0.006). Hemoglobin levels improved from baseline median 8 g/dL (IQR: 6–11) to 12 g/dL (10–14) (P < 0.001). Splenic size remained unchanged. Propranolol led to the reduction in PVD over 180 days. This suggests that ultrasound could be useful in monitoring response and compliance to beta-blockers, especially in resource-constraint areas where portal hypertension measurement facilities are unavailable.

4 April 2018 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
ESEdford Sinkala
Edford Sinkala
KZKanekwa Zyambo
Kanekwa Zyambo
EBEllen Besa
Ellen Besa
PKPatrick Kaonga
Patrick Kaonga
BNBright Nsokolo
Bright Nsokolo
PKPaul Kelly
Paul Kelly
Cirrhosis is the dominant cause of portal hypertension globally but may be overshadowed by hepatosplenic schistosomiasis (HSS) in the tropics. In Zambia, schistosomiasis seroprevalence can reach 88% in endemic areas. Bacterial translocation (BT) drives portal hypertension in cirrhosis contributing to mortality but remains unexplored in HSS. Rifaximin, a non-absorbable antibiotic may reduce BT. We aimed to explore the influence of rifaximin on BT, inflammation, and fibrosis in HSS. In this phase II open-label trial (ISRCTN67590499), 186 patients with HSS in Zambia were evaluated and 85 were randomized to standard care with or without rifaximin for 42 days. Changes in markers of inflammation, BT, and fibrosis were the primary outcomes. BT was measured using plasma 16S rRNA, lipopolysaccharide-binding protein, and lipopolysaccharide, whereas hyaluronan was used to measure fibrosis. Tumor necrosis factor receptor 1 (TNFR1) and soluble cluster of differentiation 14 (sCD14) assessed inflammation. 16S rRNA reduced from baseline (median 146 copies/µL, interquartile range [IQR] 9, 537) to day 42 in the rifaximin group (median 63 copies/µL, IQR 12, 196), P < 0.01. The rise in sCD14 was lower (P < 0.01) in the rifaximin group (median rise 122 ng/mL, IQR-184, 783) than in the non-rifaximin group (median rise 832 ng/mL, IQR 530, 967). TNFR1 decreased (P < 0.01) in the rifaximin group (median -39 ng/mL IQR-306, 563) but increased in the non-rifaximin group (median 166 ng/mL, IQR 3, 337). Other markers remained unaffected. Rifaximin led to a reduction of inflammatory markers and bacterial 16S rRNA which may implicate BT in the inflammation in HSS.

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ESEdford Sinkala
Edford Sinkala
MVMichael Vinikoor
Michael Vinikoor
KZKanekwa Zyambo
Kanekwa Zyambo
EBEllen Besa
Ellen Besa
PKPaul Kelly
Paul Kelly

1 May 2016 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
VKViolet J. Kayamba
Violet J. Kayamba
SAShibemba Aaron
Shibemba Aaron
KZKanekwa Zyambo
Kanekwa Zyambo
DMDouglas Morgan
Douglas Morgan
DHDouglas Heimburger
Douglas Heimburger
PKPaul Kelly
Paul Kelly

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
VKViolet J. Kayamba
Violet J. Kayamba
SAShibemba Aaron
Shibemba Aaron
KZKanekwa Zyambo
Kanekwa Zyambo
DMDouglas Morgan
Douglas Morgan
DHDouglas Heimburger
Douglas Heimburger
PKPaul Kelly
Paul Kelly